Introduction
Death receptors and their ligands have been implicated in the homeostasis of activated lymphocytes and tumor cells in vivo. For example, one prototypic death factor, tumor necrosis factor (TNF), can induce death in malignantly transformed cells Helson et al., 1975) . However, most cells, normal or cancerous, are resistant to TNF killing since TNF signals activate survival pathways in addition to the death cascade (Mak and Yeh, 2002; Gaur and Aggarwal, 2003) . Investigating the mechanisms regulating the balance of cell death and survival in normal cells and the perturbation of this balance in cancer cells is crucial for further understanding cancer biology and for designing new therapeutic strategies for cancer.
Normally, resistant cells become sensitized to TNF killing when actinomycin D or cyclohexamide is present (Polunovsky et al., 1994; Liu et al., 1996) , suggesting that the survival arm of TNF signaling requires de novo gene transcription and translation. NF-kB, a key transcription factor activated by TNF, plays an important role in activating survival effector genes that oppose TNF-induced cell death. Mice deficient for NFkB activation, including IKKb, Nemo/IKKg, and p65/ RelA knockouts, are embryonic lethal due to massive liver apoptosis and fibroblasts derived from these mutant mice embryos are highly sensitive to TNFinduced cell death (Beg and Baltimore, 1996; Li et al., 1999; Rudolph et al., 2000) .
Several TNF-inducible NF-kB survival genes have been identified. For example, cellular inhibitors of apoptosis proteins 1 and 2 (cIAP-1 and cIAP-2) are NF-kB target genes capable of blocking caspase activity (Chu et al., 1997; Wang et al., 1998) . Bcl-2 family members, including Bfl-1/A1, Bcl-2, and Bcl-xL, have also been demonstrated to protect cells from TNFinduced death in certain cell contexts (Jaattela et al., 1995; Zong et al., 1999; Manna et al., 2000) . However, overexpression of the aforementioned NF-kB target genes have been found to only partially protect against TNF-induced death, suggesting that multiple survival pathways are likely involved.
Platlet-derived growth factor B (PDGF-B) and PDGF-A were previously reported to be TNF-inducible genes in adenocarcinoma cells (Kalthoff et al., 1991) . In this report, we demonstrate that PDGF-B, a protooncogene, is highly induced by TNF in mouse embryonic fibroblasts (MEFs). Furthermore, we also show that this induction is completely abolished in NF-kBdeficient cells. Interestingly, giving PDGF-B to NFkB-deficient cells in culture protects these mutant cells from being killed by TNF, suggesting that PDGF-B can function downstream of NF-kB as a survival effector. Blocking PDGF-B signals in untransformed, wild-type cells does not induce robust TNF-induced killing. However, PDGF-B-transformed fibroblasts are highly susceptible to TNF-induced toxicity when PDGF-B signals are inhibited. These results provide an intriguing basis for eradicating cancer cells specifically if an anomalous survival signal that opposes death factors can be identified in these cells.
Results

PDGF-B is transcriptionally induced by TNF through NF-kB
Microarray analysis was used to identify potential TNFinducible, NF-kB-dependent target genes as previously described (Suzuki et al., 2003) . PDGF-B was a candidate gene that was strongly induced by TNF in wild-type MEFs and exhibited a 12-fold reduction in expression in TNF-stimulated NF-kB-deficient MEFs compared to wild-type cells (data not shown).
The expression pattern of PDGF-B was examined by Northern blotting. Wild-type, NF-kB-deficient (RelA/ p65 À/À ), and TRAF2 À/À -immortalized MEFs were untreated or stimulated with TNF for 2, 6, or 24 h. pdgf-b transcripts were highly induced by TNF after 2 h of stimulation in wild-type and TRAF2 À/À MEFs, but this induction was nearly abolished in RelA À/À cells ( Figure 1a) . A faint signal of pdgf-b RNA was visible in RelA À/À MEFs in repeated experiments and after long exposure (data not shown), suggesting that the mutant MEFs did not lose the expression of this gene. A similar defect in TNF-induced PDGF-B expression was also observed in NEMO/IKKg À/À MEFs (data not shown). PDGF-B is a growth factor that targets specific tissues, including fibroblasts, pericytes, and smooth muscle cells. An NF-kB-binding site in the pdgf-b promoter was found to be critical for PDGF-B expression in response to shear stress, suggesting that PDGF-B is a direct transcriptional target of NF-kB (Khachigian et al., 1995) . In contrast, PDGF-A was mildly induced by TNF, but there was no difference in induction between wild-type and RelA À/À MEFs by Northern blot analysis (data not shown).
PDGF-B is a proto-oncogene, and signals through PDGF receptors a and b (PDGFRa/b) (Gazit et al., 1984; Heldin and Westermark, 1999) . To investigate whether the induction of pdgf-b transcripts leads to activation of PDGFR, we examined tyrosine phosphorylation of PDGFRb in response to TNF. To reduce background phosphorylation caused by serum, we adapted MEFs to knockout serum replacement media (Invitrogen) for this assay. We observed an induction of PDGFRb phosphorylation in wild-type cells starting 2 h after TNF stimulation (Figure 1b) . PDGFRb activation peaked between 2 and 4 h and persisted for up to 8 h after TNF treatment (Figure 1b and data not shown), corroborating the time course of TNF-induced PDGF-B expression observed by Northern blotting. In contrast, no PDGFRb activation was observed in RelA À/À MEFs stimulated with TNF ( Figure 1b) . It is interesting to note that the kinetics of PDGFRb phosphorylation mediated by TNF stimulation were slower but more prolonged than those induced by exogenous PDGF-B treatment (Figure 1c ).
PDGF-B rescues NF-kB-deficient MEFs from TNFinduced cell death PDGF-B triggers a variety of signals including activation of the PI3K-Akt/PKB and ERK/MAPK pathways, and a wide range of cellular responses including proliferation and survival (Heldin and Westermark, 1999) . Interestingly, one survival pathway that has been intensively studied and well documented is PDGF-B induction of Akt/PKB leading to eventual activation of NF-kB (Romashkova and Makarov, 1999; Shimamura et al., 2002; Gustin et al., 2004) . Here, we suggest a distinct survival pathway where PDGF-B could potentially function downstream of NF-kB. Since NEMO À/À or RelA À/À MEFs are sensitive to TNF-induced apoptosis (Beg and Baltimore, 1996; Rudolph et al., 2000) , reconstitution of PDGF-B in NF-kB-deficient cells may rescue these cells from death if PDGF-B is a dominant survival factor that TNF fails to induce in or RelA À/À MEFs were protected from TNF-induced killing when PDGF-B was added to the culture ( Figure  2a and b, and data not shown). For example, from 4 independent experiments, only 40% of NEMO À/À MEFs were viable after 16 h of TNF treatment. In contrast, 80% of NEMO À/À cells were viable when treated with both TNF and PDGF-B concurrently ( Figure 2a) . As expected, serum-starved littermate-matched control wild-type MEFs were not affected by TNF stimulation (data not shown).
PDGF-B is a major growth factor present in serum. Consistent with the protective effect of PDGF-B and serum, we observed that prolonged culture and propagation of NEMO À/À or RelA À/À MEFs using 10% fetal calf serum (FCS) protected them from TNF killing (Figure 2a) , in contrast to serum-starved conditions. To investigate whether other growth factors also resulted in this protective effect, we tested PDGF-A, PDGF-B, IGF-1, EGF, FGF, and VEGF. Among these growth factors, we observed detectable PKB/Akt phosphorylation 15 min after stimulation with PDGF-B, PDGF-A, and IGF-1 in wild-type MEFs (data not shown). However, only PDGF-B, and to a lesser extent IGF-1, was able to protect NEMO À/À cells from TNF-induced death (Figure 2a ). IGF-1 and PDGF-B together did not protect NEMO À/À cells from TNF significantly more than PDGF-B alone (data not shown). Sensitization of NF-kB-deficient cells to TNF was not entirely due to starvation or lack of serum, as TNF-induced NEMO À/À cell death could be reproduced in knockout serum replacement media, albeit to a lesser extent, and that this death could also be rescued by PDGF-B (data not shown). This replacement media can support cell growth 
Inhibition of PDGFR signaling sensitizes wild-type MEFs to TNF-induced cell death
We next examined whether PDGF-B is essential for NFkB-mediated protection against TNF-induced death. Imantinib mesylate, also known as STI571 or Gleevec, is a small molecule tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class with high specificity to Abl, c-kit, and PDGFR tyrosine kinases (Manley et al., 2002) . Treatment of MEFs with STI571 (10 mM) was sufficient to reduce phosphorylation of PDGFRb induced by exogenous PDGF-B and abolish regular serum-induced PDGFRb activation (Figure 3a ), which is similar to levels induced by TNF. PDGFR inhibition in wild-type MEFs by STI571 did not significantly affect cell viability, but sensitized the cells to TNF-induced death by day 3 in low serum ( Figure 3b ).
Susceptibility to STI571 and TNF treatment appeared to vary between different wild-type MEF lines and different primary MEFs, but in general, only a fraction of cells were sensitized to TNF killing by PDGFR inhibition (Figure 3c and data not shown). This suggested that while PDGF-B may be adequate and essential to protect a subpopulation of cells, the majority of cells contain multiple survival pathways that may compensate for the loss of one pathway.
To investigate whether the sensitization effect of STI571 was due specifically to the inhibition of PDGFR signaling in MEFs, we examined the sensitivity of Abldeficient MEFs to TNF and STI571 treatment and found that it was comparable to that of wild-type MEFs (Figure 3d ). c-kit is another target kinase that STI571 can inhibit, however, c-kit expression was not observed in MEFs by Western blotting (data not shown). We also acquired D64406, a PDGFR inhibitor which is a 
(c) Left panel shows data from day 3 in 1% FCS-DMEM for the wild-type MEF death assay described in (b). Po0.04, 6 Po0.008. (e) Wild-type MEFs were cultured in 1%FCS-DMEM and treated with TNF, D64406, TNF þ D64406, or left untreated. Cell viability was assayed after 3 days as previously described. Data are mean7s.e.m (n ¼ 2).
7 Po0.04, Po0.02. For (c-e), the percentage of viable cells left after treatment is normalized to the control (no treatment) at day 3 bis(1H-2-indoyl)methanone derivative with a distinct chemical structure from STI571 (Mahboobi et al., 2002) . The dosage of D64406 was determined by assaying the inhibition of PDGFRb phosphorylation by Western blotting (data not shown). We observed that D64406 sensitized cells to TNF-induced death with similar kinetics and to a similar degree as STI571 (Figure 3e ). Taken together, our results support our hypothesis that PDGF-B is a key survival factor that opposes TNFinduced cytotoxicity downstream of NF-kB, and that multiple survival pathways likely function in wild-type, untransformed MEFs.
Tumor cells transformed with PDGF-B are more susceptible to TNF-induced killing when PDGFR signaling is blocked
The cell survival function of NF-kB is often associated with tumorigenesis, however, few NF-kB target gene products can transform cells (Karin et al, 2002; Cao and Karin, 2003) . Since PDGF-B is a proto-oncogene, we examined whether tumor cells transformed by the overexpression of PDGF-B are more resistant to TNFinduced cytotoxicity. We compared 3T3-PDGF-B (a mouse fibroblast line constitutively overexpressing and transformed by human PDGF-B/sis (Gazit et al., 1984) and its parental NIH-3T3 cell line. Interestingly, NIH-3T3 was the only MEF-derived cell line that we have examined where no endogenous PDGF-B expression was detectable by Northern blotting (data not shown). While other MEF lines were relatively TNF-resistant (Figure 3 ), TNF treatment alone was able to induce a mild degree of cell death in untransformed NIH-3T3 cells (Figure 4a ). In contrast, transformed 3T3-PDGF-B cells were completely resistant to TNF killing (Figure 4a) .
We then investigated whether 3T3-PDGF-B tumor cells could be sensitized to TNF-induced death by STI571 blockade, and if so, how the susceptibility of these cells to TNF compared to wild-type, untransformed cells lacking constitutive PDGF-B signaling. Treatment with 10 mM STI571 alone was capable of abrogating PDGF signals in the tumor cells, and only caused a mild degree of cell death under low serum conditions (Figure 4b ). In contrast, STI571 plus TNF greatly compromised the viability of 3T3-PDGF-B cells by day 2, and almost completely eliminated these cells by day three (Figure 4c and d) . Compared with the most sensitive wild-type, untransformed MEFs (day 2, 92%; day 3, 40% viability), STI571 and TNF exhibited a more pronounced cytotoxic effect on 3T3-PDGF-B cells (day 2, 31%; day 3, 7% viability) (Figures 3c and 4d) . These results suggest that 3T3-PDGF-B cells, compared to untransformed cells, depend more greatly on PDGF-B signals to protect against death receptor-induced cytotoxicity. Interestingly, TNF was still able to induce NF-kB binding in PDGF-B-transformed tumor cells (Figure 4e ), suggesting that these cells are still capable of inducing an arsenal of survival target genes against TNF similar to wild-type, untransformed cells, despite their reliance on PDGF-B.
Since STI571-sensitized death occurs over a relatively prolonged time course after TNF treatment, we investigated whether this cell death involved apoptosis. Propidium iodide (PI) staining of permeabilized 3T3-PDGF-B cells treated with TNF plus STI571 revealed a sub-G1 DNA peak consistent with the occurrence of apoptosis (Figure 5a ). Annexin V staining to detect phosphatidyl serine exposure (Figure 5b ) and caspase-3 activation assays (Figure 5c ) also confirmed the presence of apoptosis. Consistent with aforementioned results, we observed slower kinetics for caspase-3 activation in the wild-type MEF line (caspase-3 activity detectable by 24 h), than in the 3T3-PDGF-B line (caspase-3 activity detectable by 6 h), when treating with the STI571 plus TNF (Figure 5c ). It is possible that apoptosis only partly accounts for the cell death observed in our experiments as some dead cells (PI þ ) were not stained by Annexin V, and as the sub-G1 DNA peak is small relative to the degree of death observed (Figure 5a and b) .
Our results show that malignant cells transformed with PDGF-B, while mildly sensitive to STI571-induced death, can be completely eradicated by TNF plus STI571 through mechanisms that include programmed cell death. The fact that these transformed cells, which still possess TNF inducible NF-kB activation (Figure 4e) , become dependent on a specific survival signal such as PDGF-B for protection against death factors is intriguing, and may have potential therapeutic implications.
Discussion
The ability of growth factors to suppress death receptormediated killing has been exemplified in different cellular contexts and stimulation conditions. For example, IGF-1 has been found to suppress myc-induced killing by blocking the death pathway downstream of CD95/Fas (Harrington et al., 1994; Hueber et al., 1997; Juin et al., 1999) , and EGF signaling is capable of inhibiting TNF-or TRAIL-mediated apoptosis in epithelial cancer cell lines (Gibson et al., 2002; Smith et al., 2002) . However, these studies typically involved stimulation with exogeneous growth factors. In this study, we demonstrate that TNF stimulation of wildtype, untransformed MEFs strongly induces endogenous PDGF-B, which promotes the activation of a survival pathway instead of the suicide route. In this scenario, PDGF-B likely functions in an autocrine or paracrine manner, and represents a key switch in the death versus survival decision for fibroblasts confronted with TNF challenge.
One prevalent theory regarding survival pathways involves a growth factor trigger, such as PDGF-B stimulation, followed by activation of Akt/PKB and subsequent activation of the IkB kinase complex, leading to NF-kB activation and transcription of its target genes (Romashkova and Makarov, 1999; Shimamura et al., 2002) . In this report, we show that PDGF-B is actually an inducible target of NF-kB. Susceptibility of NF-kB-deficient cells to TNF killing can be reverted (Shimamura et al., 2002) . TNF-induced PDGF-B signaling also demonstrates slower and elongated kinetics in contrast to exogeneous PDGF-B stimulation (Figure 1b and c) . Whether this endogenous signal is sufficient to trigger a detectable, second-wave of NF-kB activation remains to be determined.
PDGF-B is equivalent to the c-sis oncogene, and autocrine transformation by PDGF-B is linked to several cancers, including human glioblastoma and dermatofibrosarcoma protuberans (DFSP) (Vassbotn et al., 1994; Simon et al., 1997) . In DFSP, a translocation fuses exon 2 of PDGF-B with collagen 1a1, resulting in constitutive expression of the mature PDGF-B chain (Simon et al., 1997) . Certain cell lines have been derived from DFSP patients and passed numerous times through immune compromised mice, and these cells are known to be sensitive to STI571 suppression (Sjoblom et al., 2001) . Interestingly, a DFSP cell line we have obtained (Sjoblom et al., 2001) appears to produce a small amount of TNF (data not shown) and possibly other death ligands on its own. The ability of tumor cells to produce TNF is not uncommon, and in some cases this is believed to help promote tumor growth and progression in vivo (Balkwill, 2002) . If the key survival factor opposing the effect of death factors is blocked in tumor cells, TNF may then have an alternative effect and become toxic to these transformed cells. Indeed, the growth of xenograft DFSP tumors in nude mice is significantly suppressed by in vivo admin- istration of STI571, mediated in part through apoptotic responses (Sjoblom et al., 2001) .
PDGF-B-transformed cells are considerably more sensitized by STI571 to TNF killing than untransformed cells. The fact that STI571 alone can induce death preferentially in tumor cells cannot sufficiently explain this phenomenon. The effect of STI571 alone on 3T3-PDGF-B cells is minor compared to the effect of STI571 and TNF on the same transformed cells (79% versus 7% viability by day 3, Figure 4d ). Furthermore, TNF alone cannot kill any PDGF-B-transformed cells even in low serum and over a prolonged time course, whereas in the presence of STI571, TNF almost completely eradicates 3T3-PDGF-B cells. These data suggest that blockade of PDGF-B signals in these tumor cells is required to trigger and then synergize with the cytotoxic effects of TNF.
While apoptosis was detected in STI571-and TNFmediated cell death, the prolonged time course required for cell death in addition to the presence of PI-positive annexin-V-negative cells (Figure 5b) , and a smaller than expected sub-G1 DNA peak (Figure 5a ), suggests that other forms of death may be involved. PDGF-B may protect cells from necrosis and autophagic death, especially since starvation appears to affect the balance of cell death and survival when TNF and STI571 are both present. Recent studies have implicated death receptors in the induction of autophagy and autophagic cell death (Prins et al., 1998; Mills et al., 2004) , and one study has also shown that inhibition of PDGF signaling in malignant glioma cells can increase autophagy (Takeuchi et al., 2004) .
It is unclear why PDGF-B, but not the other growth factors tested, confers a survival effect in TNFchallenged NF-kB-deficient MEFs. The inability of other growth factors to effectively mediate rescue might be due to treatment effects in terms of dose and scheduling. While IGF-1 was able to protect NF-kBdeficient MEFs from TNF to a minor extent, cotreatment with both PDGF-B and IGF-1 did not confer significantly more protection than PDGF-B alone. This suggests that IGF-1 may activate pathways shared by PDGF-B, and that PDGF-B may activate unique survival pathways that oppose TNF death signals. Various tissue types may also rely on different sets of growth factors for survival. Furthermore, there may be a preference for PDGF-B versus PDGF-A in the context of survival signaling since PDGF-B is able to bind both PDGFRa and PDGFRb, whereas PDGF-A only binds PDGFRa Heidaran et al., 1993) . While there is significant overlap in the signaling downstream of PDGFRa and b, there are also identified differences (Beckmann et al., 1988; Heidaran et al., 1993; Ekman et al., 1999) . The relative contribution of signaling through the two PDGF receptor types towards cell survival in response to TNF may be interesting for future studies.
The concept that tumor cells rely heavily on the signaling pathways contributing to their transformed phenotype is not unprecedented. This study is significant since our results suggest that such dependence may apply to cell protection and survival, particularly against death receptor signals. If this proves to be a general principle, then identification of key survival factors in each tumor may become a critical task to control tumor growth or progression. Since many tumors produce or stimulate the surrounding tissues to produce TNF and/ or other death factors (Bruserud et al., 1995; Balkwill, 2002; Mochizuki et al., 2004) , our findings may be applicable to many human malignancies.
Materials and methods
Cell culture
We derived and immortalized MEFs from E12.5-E14.5 mouse embryos. NIH-3T3-PDGFB cells and Abl À/À fibroblasts were kindly provided by Stuart Aaronson at Mount Sinai School of Medicine in New York and Jean Wang at the University of California at San Diego, respectively. Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FCS (Sigma lots 033K8407, 052K8411, 011K8409; Gibco lot 1168554) and 0.1% b-mercaptoethanol (Sigma). Low serum media containing 1% FCS, or serum starvation media containing 0.1% FCS, were used where indicated. We have observed variation in cell sensitivity to STI571 depending on the serum batch used, so low serum conditions and STI571 dosage (1-10 mM) may need to be optimized. Cells were also cultured in DMEM supplemented with 10% Knockout Serum Replacement (10% KOSR-DMEM; Invitrogen), 0.1% b-mercaptoethanol, and 2 mM l-Gln (Invitrogen) to reduce background PDGFR activation.
Northern blot analysis
We treated wild-type, RelA/p65
, and TRAF2 À/À MEFs with 10 ng/ml mouse TNFa (R&D Systems) for 0-24 h. We extracted total RNA with TRIzol reagent and the protocol supplied by the manufacturer (Invitrogen). RNA (20 mg) of RNA was separated with a 1% denaturing formaldehyde agarose gel and transferred to a Hybond N membrane (Amersham Biosciences). cDNA probes specific for PDGF-B Figure 6 Proposed model for PDGF-B-mediated survival signaling induced by TNF through NF-kB. TNF stimulation leads to activation of NF-kB and transcription of a host of survival factors, including the growth factor PDGF-B. Endogenous PDGF-B induced by TNF is able to stimulate PDGFR. Activation of PDGFR results in survival signals that oppose TNF-induced cytotoxicity and GAPDH were labeled using the Rediprime DNA labeling system (Amersham Biosciences), and hybridized to the membrane in Church-Gilbert Buffer (7% SDS, 1% BSA, 0.5 M NaHPO 4, 1 mM EDTA). We stripped the membrane between probes by boiling in 0.25% SDS for 10 min and incubating at 651C for 30 min.
Western blot analysis
MEF cells were seeded at a density of 5 Â 10 5 cells/10 cm plate. We acclimatized cells to 10% KOSR-DMEM by changing to 1%FCS-DMEM for 3-6 h followed by 12 h in 10% KOSR-DMEM before stimulation with 10 ng/ml TNFa or 30 ng/ml recombinant rat PDGF-B (Sigma). We lysed cells in TXE buffer (50 mM Tris pH 8.0, 150 mM NaCl, 20 mM EDTA, 1% Triton X-100, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium fluoride, 1 mM sodium o-vanadate), and determined protein concentration using the Bio-Rad Protein Assay (BioRad) to equalize samples. 1 mg anti-PDGFRb (Upstate) and protein sepharose A Cl-4B (Amersham Biosciences) was used to immunoprecipitate the receptor from 200-300 mg protein. Samples were fractionated by SDS-PAGE, and transferred onto PVDF membrane (Roche). The membrane was probed with antiphosphotyrosine polyclonal antibody (1 : 1000, Signal Transduction Laboratories) to detect phospho-PDGFRb or antiPDGFRb polyclonal antibody (1 : 1000, Upstate) to detect total PDGFRb, and visualized with horse-radish peroxidase conjugated antibody to rabbit IgG (1 : 5000, Amersham Biosciences) using the ECL system (Amersham Biosciences). We stripped membranes between probes with 0.1 M glycine pH 2.5 for 40 min at 551C.
FACS death assays
To determine whether PDGF-B could rescue NF-kB-deficient cells from TNF killing, NEMO/IKKg À/À MEFs were seeded at a density of 8 Â 10 4 cells/well in a 12-well plate, and serum starved (0.1%. FCS in DMEM) for 6-8 h. We treated cells in starvation media with 10 ng/ml TNF alone, 30 ng/ml PDGF-B alone, TNF and PDGF-B simultaneously, or left them untreated for 16 h. Similarly, 10 ng/ml TNF was also combined with rat PDGF-A (R&D Systems), mouse IGF-1, mouse EGF, human bFGF, mouse VEGF (Sigma, all used at 100 ng/ml). To determine whether STI571 sensitized cells to TNF-induced cell death, we seeded 2.5 Â 10 4 wild-type MEFs and 5 Â 10 4 3T3-PDGFB cells/well in 12-well plates. We dissolved 100 mg tablets of imantinib mesylate (STI571 or Gleevec, Novartis) into distilled water and filter sterilized for a 10 mM stock. Cells were treated with 10 mM STI571, 10 ng/ml TNF, STI571 plus TNF, or left untreated in either 10% FCS-DMEM or 1% FCS-DMEM. D64406 (Calbiochem) was reconstituted in DMSO as a 3 mM stock. Cells were treated with 7 mM D64406 with and without TNF in the manner just described.
After treatment, cells were harvested, pelleted, and washed with 3% FCS in PBSÀ/À. Cells were stained with 1 mg/ml PI (Sigma) to determine the percentage of viable cells (PI-negative) remaining after treatment. To identify sub-G1 DNA peaks, cells were treated as previously desribed and resuspended in 250 ml of 0.1% sodium citrate, 0.1% Triton X-100, with 50 mg/ml PI, and incubated overnight at 41C. For AnnexinV/PI staining, cells were harvested, washed, and resuspended in 100 ml of binding buffer (10 mM HEPES/ NaOH pH 7.4, 140 M NaCl, 2.5 mM CaCl 2 , 5 mg/ml PI) with 1 ml of AnnexinV-FITC (Pharmingen) per sample. Cells were incubated for 15 min at room temperature in the dark, followed by the addition of 400 ml of binding buffer. Samples were analysed by flow cytometry (FACScalibur; Becton Dickenson) with CellQuest software (Becton Dickenson). Sub-G1 peaks were identified by ModFit LT software (Verity Software House, Inc.).
Caspase-3 activation assay
Cells were treated with 10 mM STI571, 10 ng/ml TNF, STI571 and TNF simulataneously, or left untreated in 1% FCS-DMEM for 6-24 h. 1 Â 10 6 cells/ sample were analysed for caspase-3 activation using the BD Biosciences ApoAlert Caspase 3 Fluorescence Assay kit according to the manufacturer's instructions.
Electrophoretic mobility shift assay 1 Â 10 6 3T3-PDGFB cells were seeded into 10 cm plates. Cells were left untreated or stimulated with 10 ng/ml TNF in 10% FCS-DMEM. Nuclear extracts were prepared and analysed for NF-kB activation via gel shift as previously described (Yeh et al., 1997) .
Satistical analysis
Data are reported at mean7s.e.m. Duplicates or triplicates were performed within each individual experiment. P-values for statistical significance were calculated using the Student's ttest, and values of Po0.05 were considered significant.
